Investing.com - BMO Capital reiterated an Outperform rating and $600.00 price target on Vertex Pharmaceuticals stock (NASDAQ:VRTX) following a label update for products containing ivacaftor. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results